Full-Time

Medical Science Liaison

Respiratory, Pulmonary, North Texas, New Mexico, Arizona

Posted on 10/3/2025

Deadline 11/1/25
Sanofi

Sanofi

10,001+ employees

Global pharma company; vaccines and R&D

Compensation Overview

$144.8k - $209.1k/yr

No H1B Sponsorship

Remote in USA

Remote

Must reside within posted territory; territory listed as Midwest (MO, IA, AR, OK, MN) which conflicts with North Texas, NM, AZ; role is remote/field with possible travel.

Category
Medical, Clinical & Veterinary (1)
Requirements
  • Masters degree within a scientific or clinical background or related field required. PharmD, PhD or other doctoral-level degree preferred.
  • Minimum 2 years previous pharmaceutical industry / biotech experience
  • Minimum 1-year previous MSL experience highly preferred.
  • Minimum 1-year respiratory disease related clinical experience - OR - minimum 1-year Immunology specialty experience highly preferred.
  • Valid driver’s license with a clean driving record and ability to pass a complete background check.
  • Driving a company car in a safe manner to daily meetings and appointments is required.
  • Responsible for operating the motor vehicle using safe driving practices, knowledge of and compliance with all company policies, and obeying all traffic laws.
Responsibilities
  • Engages external stakeholders on medical and scientific information exchange for the therapeutic area during a one-on-one interactions and group settings, exhibiting excellent scientific and clinical knowledge
  • Uses strong knowledge of relevant diseases and disease management protocols, healthcare environment and competitors to articulate the medical and scientific value of our products with external experts.
  • Establishes robust, long-term peer relationships with Key Opinion Leaders and other stakeholder partners
  • Actively engages with appropriate stakeholders on medical, clinical, epidemiologic, and scientific topics to advance their understanding of the disease by sharing information and answering questions based on approved material within Regulatory guidelines.
  • Engages with appropriate stakeholders to understand the state of healthcare policies and guidelines as they relate to clinical practices at a local, state, regional, federal, or national level.
  • Uses defined systems to maps, identify, profile, and prioritizes stakeholders in line with the therapeutic area medical plan and looks for opportunities to collaborate and build a value-based partnership addressing the HCPs therapeutic goals.
  • Effectively utilizes the Scientific Engagement Model to plan territory and individual stakeholder (Key Opinion Leaders, payers, HCP etc.) medical strategy and engagement interaction plans consistent with the Field Base Medical Activity Plan and medical function priorities.
  • Effectively utilizes the Scientific Engagement Model for attending and establishing a Sanofi Medical presence at relevant scientific congresses, symposia as directed.
  • Organizes educational meetings or local scientific advisory boards when requested.
  • Support speakers training to ensure continued scientific support in the field.
  • Responds to unsolicited request for medical information associated with supported products and disease state area.
Desired Qualifications
  • Candidates with relevant respiratory clinical experience consisting of asthma, COPD and immunology clinical environment may be considered.
  • Clear understanding of medical practice, clinical decision making, and healthcare systems related to patient care.
  • Ability to interpret key scientific data and translate this information to meet educational and research needs.
  • Demonstrated ability to address educational and research needs through delivery of cutting edge scientific/evidenced based data.
  • Understand the design and execution of research studies.
  • Exemplary communication and presentation skills.
  • Experience in working on multi-disciplinary teams and managing significant volume of projects.
  • Actively listens to others and is adept at confidently stating expert opinion while respecting the positions of others - can exert diplomacy while standing firm on a position.
  • Utilizes effective, professional communications to cultivate strong working relationships with internal and external colleagues, flexible in own approach to people and situations.
  • Skillfully plans, prioritizes, and executes multiple responsibilities and projects.
  • Demonstrates effective leadership skills (by example and through accomplishments), steps forward to handle challenges within scope of authority.
  • Deep understanding and knowledge of local regulations and codes of practice for pharmaceutical industry, in particular as they apply to the non-promotional activities of this role.
  • Demonstrates scientific expertise - stays abreast of data, treatment trends, and new information in the profession and ability to articulate therapeutic knowledge and translate expert feedback into appropriate insights.
  • Knowledge of relevant healthcare systems, the evolving medical landscape, regulatory and payer environment, public health and industry trends.
  • Proficiency in digital tools.

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Dupixent and a 75-plus project pipeline support continued growth and optionality.
  • Sarclisa’s outpatient-friendly injector can expand adoption in home and clinic settings.
  • Efdoralprin alfa and other rare-disease assets can monetize recombinant, non-plasma technologies.

What critics are saying

  • Dupixent concentration leaves Sanofi exposed to payer pressure, label setbacks, and biosimilar erosion.
  • Late-stage pipeline failures can destroy years of R&D spending and compress valuation.
  • AI partnerships and platform investments require execution; underperformance wastes capital and time.

What makes Sanofi unique

  • Sanofi combines pharmaceuticals, vaccines, and biologics across immunology, oncology, and rare diseases.
  • Its Sarclisa on-body injector approval differentiates treatment delivery for multiple myeloma patients.
  • Sanofi is building AI capabilities through Owkin, Snowflake, and Toronto expansion.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Sanofi who can refer or advise you

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Novo Holdings
May 4th, 2026
Novo Holdings joins $165 million crossover financing for Windward Bio to advance pipeline of long-acting immunology therapies with best-in-disease potential.

Novo Holdings joins $165 million crossover financing for Windward Bio to advance pipeline of long-acting immunology therapies with best-in-disease potential. * Led by OrbiMed, with participation from RA Capital Management, Janus Henderson Investors, Sanofi Ventures, and existing investors, including Novo Holdings * Proceeds will advance lead candidate WIN378 into Phase 3 and WIN027 into respiratory and dermatology studies by Q4 2026 * WIN378 has the potential to be the first-to-market ultra long-acting anti-TSLP antibody for asthma and COPD * WIN027 is a long-acting bispecific targeting TSLP and IL-13 with best-in-disease efficacy potential Windward Bio, a private, clinical-stage biotechnology company committed to improving outcomes for people living with serious immunological diseases, today announced an upsized $165 million crossover financing led by OrbiMed, with participation from existing Series A investors including Novo Holdings, Blue Owl Healthcare Opportunities, SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, and Pivotal bioVenture Partners. The financing also included new investors RA Capital Management, Janus Henderson Investors, and Sanofi Ventures. Proceeds will significantly extend the company's cash runway and enable multiple clinical readouts in the next 12 months. Since launching in January 2025, Windward Bio has in-licensed 2 clinical-stage assets, raised $365 million, and rapidly advanced both programmes[RW1] in the clinic. WIN378, the lead programme, is a next-generation, fully human monoclonal antibody that potently binds to the thymic stromal lymphopoietin (TSLP) ligand. This well-validated cytokine plays a key role in the development and progression of a wide array of immunological diseases. WIN378 has the potential to be the first-to-market, ultra long-acting anti-TSLP antibody with twice-yearly dosing. The financing will accelerate the development of WIN378, which is currently being studied in the Phase 2/3 POLARIS programme in asthma. The Phase 2 dose-ranging component of POLARIS is fully recruited, with initial data expected in the second half of 2026. The first Phase 3 study of WIN378 is expected to begin in the fourth quarter of 2026. The Phase 2 SIRIUS study in chronic obstructive pulmonary disease (COPD) is anticipated to start in the second quarter of 2026. WIN027, the second programme, is a highly potent, long-acting bispecific antibody targeting both TSLP and interleukin-13 (IL-13) - two well-validated and synergistic drivers of inflammation in severe asthma, COPD, and atopic dermatitis. WIN027 is currently in a Phase 1 study with data readout expected by the end of 2026. The financing will support multiple proof-of-concept studies across respiratory and dermatology indications starting in in the fourth quarter of 2026. "We are excited to expand our shareholder base of top-tier investors to include RA Capital, Janus Henderson, and Sanofi Ventures" said Luca Santarelli, MD, Founder, Chief Executive Officer, and Board Chair of Windward Bio. "This financing further strengthens our balance sheet and allows us to further advance our programmes of next-generation therapies for patients living with serious respiratory and dermatological diseases." Naveed Siddiqi, Senior Partner, Venture Investments, Novo Holdings, said: "Spearheaded by a highly experienced clinical and commercial leadership consisting of serial entrepreneurs, Windward Bio has made rapid progress since it launched in 2025, including bringing in a second clinical stage asset, WIN027. There is much more to be done towards improving dosing frequency and outcomes for the benefit of patients suffering from serious and chronic immunological conditions, and as a significant shareholder, we are pleased to support Windward Bio as it advances its innovative and developing pipeline into late-stage trials." About WIN378 WIN378 is a next-generation, fully human monoclonal antibody that potently inhibits the TSLP ligand. This clinically validated target plays a key role in the development and progression of a wide array of immunological diseases, including asthma and COPD. WIN378 has been engineered to achieve half-life extension (HLE) and to have a silenced effector function. It has been studied in a Phase 1 trial, which confirmed an extended half-life suitable for twice-yearly dosing, demonstrated a low rate of antidrug antibodies, and was safe and well tolerated up to the highest dose tested. WIN378 is administered subcutaneously. Windward Bio licensed the global rights (excluding Greater China and several Southeast and West Asian countries) for WIN378 from Kelun Biotech (also known as SKB378) and Harbour BioMed (also known as HBM9378). WIN378 is currently being evaluated in the POLARIS Phase 2/3 asthma study with initial readouts expected in the second half of 2026. A Phase 2 study in COPD is anticipated to begin in the second quarter of 2026. About WIN027 WIN027 is a potential best-in-class, humanised bispecific monoclonal antibody with subpicomolar affinity for TSLP and IL-13, well-validated targets in immunological conditions. It has been engineered to achieve an extended half-life and enable less frequent dosing. Through this dual, long-acting inhibition, WIN027 is designed to set a new standard of efficacy in conditions such as asthma, COPD, and atopic dermatitis, potentially delivering deeper and more durable disease control than existing biologics. WIN027 is currently in Phase 1. Windward Bio licensed the global rights (excluding Greater China) for WIN027 from Qyuns Therapeutics (also known as QX027N). About Windward Bio Windward Bio is a clinical-stage biotechnology company with deep discovery, development, and commercialization expertise committed to transforming the treatment of people living with serious immunological conditions. Its lead programme is WIN378, a potential best-in-disease, ultra long-acting anti-TSLP monoclonal antibody currently in a Phase 2/3 trial for asthma. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bispecific with broad therapeutic potential across immunological diseases, which is currently in Phase 1. The company is building a discovery pipeline of long-acting bispecific antibodies, targeting validated biology in respiratory and dermatological conditions. Media Enquiries Marie-Louise Jersin, Senior Communications Lead, [email protected]

Yahoo Finance
Apr 13th, 2026
Dupixent approved in EU as first targeted medicine for chronic spontaneous urticaria in children aged 2-11

Regeneron Pharmaceuticals and Sanofi announced that the European Commission has approved Dupixent (dupilumab) for treating moderate-to-severe chronic spontaneous urticaria in children aged 2 to 11 years. The approval applies to patients with inadequate response to histamine-1 antihistamines who are naïve to anti-immunoglobulin E therapy. This expands Dupixent's existing EU approval for CSU, which previously covered adults and adolescents aged 12 and older. The drug is now approved for children under 12 across four chronic diseases driven partly by type 2 inflammation. The approval is based on data from the LIBERTY-CUPID clinical trial programme, including efficacy data extrapolated from two Phase 3 adult trials and pharmacokinetic, safety and efficacy data from the CUPIDKids Phase 3 trial in children aged 2 to 11.

The Associated Press
Apr 13th, 2026
EU approves Sanofi and Regeneron's Dupixent as first targeted medicine for young children with chronic urticaria

The European Commission has approved Dupixent (dupilumab) for treating moderate-to-severe chronic spontaneous urticaria in children aged two to 11 years with inadequate response to antihistamines. Developed by Sanofi and Regeneron, this marks the first targeted medicine for young children with the condition in the EU. The approval, based on the LIBERTY-CUPID clinical study programme, expands Dupixent's CSU indication to children as young as two years. The drug is now approved for children under 12 across four chronic diseases driven partly by type 2 inflammation. Clinical studies showed Dupixent significantly reduced urticaria activity, including itch and hives, compared with placebo at Week 24. Safety results were consistent with Dupixent's known profile in dermatological indications. A supplemental biologics licence application is under review in the US for the same patient population.

The Associated Press
Mar 31st, 2026
Sanofi's Rezurock approved in EU for chronic graft-versus-host disease treatment

The European Commission has granted conditional marketing authorisation for Sanofi's Rezurock (belumosudil) to treat chronic graft-versus-host disease in adults and children aged 12 years and older weighing at least 40 kg. The treatment is approved for patients when other options provide limited benefit or have been exhausted. The approval follows a positive opinion from the European Medicines Agency and is based on the ROCKstar phase 2 study, which demonstrated a 74% overall response rate. Nearly half of chronic GVHD patients require third-line treatment, yet therapeutic options have remained limited in the EU. Rezurock is already approved in 20 countries, including the US, UK and Canada. More than 20,000 patients have been treated with the medicine since its first US approval in July 2021.

Yahoo Finance
Mar 30th, 2026
Bernstein initiates Sanofi with 'outperform' rating, $123 target price

Bernstein analyst Justin Smith has initiated coverage of Sanofi with an "Outperform" rating and a price target of €110, representing 37% upside from current levels. The analyst believes the French biopharmaceutical company's new chief executive will unlock shareholder value. Sanofi appointed Belén Garijo, former CEO of Germany's Merck KGaA, as its new chief executive in February. The 65-year-old Spanish executive will take charge in late April, replacing Paul Hudson after his six-year tenure. The company says Garijo will strengthen productivity, governance and innovation capacity in research and development. Sanofi shares have declined over 4.5% since the beginning of 2025. The stock trades at a forward price-to-earnings ratio of 9.26.

INACTIVE